GAO: Antipsychotic overuse "widespread" for dementia

There is widespread overuse of psychiatric drugs by older Americans with Alzheimer's disease or dementia who live at home or in assisted living facilities, according to a new General Accountability Office (GAO) report. » Details

First atypical antipsychotic approved for pediatric patients with bipolar I disorder in 5 years

FDA has approved asenapine (Saphris, Actavis) for treatment of manic or mixed episodes of bipolar I disorder in pediatric patients, aged 10 to 17 years. » Details

Continuing Education

2015 Updates on the national guidelines for diabetes management and related disorders

Last month and this month pharmacists will be able to learn about the latest developments in diabetes treatment and management. Pharmacists can earn up to 4 hours of CPE credit with two monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics. The goal of this month’s activity is to discuss the recent updates of national U.S. guidelines for diabetes management, including hypertension and cholesterol management in patients with diabetes, in order to empower pharmacists in clinical decision-making.

Read/print the article: Click here

Take the test: Click here to log in with the Session Code 15DT16-TAJ88.

Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

Lemtrada: A new treatment option for multiple sclerosis

Lemtrada (alemtuzumab), a first-in-class monoclonal antibody against CD52, is a new treatment option for patients who have had an inadequate response or intolerability to other multiple sclerosis therapies. » Read more

POLL:

A new class of biologics in the PCSK9 Inhibitors likely will be approved for treating high cholesterol. How are you preparing?

• Anticholinergic drugs linked to higher risk for pneumonia in elderly

• First therapy for pediatric high-risk neuroblastoma approved by FDA

RESOURCES

Latest Clinical News